Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
Clinical trial NCT02563002 · COMPLETED
Trial details
- NCT number
- NCT02563002
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-11-30
- Primary completion
- 2021-02-19
- Enrollment
- 307
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.